# Y-6 Sublingual Tablets for Acute Penetrating Artery Infarction

> **NCT07721545** · PHASE2,PHASE3 · NOT_YET_RECRUITING · sponsor: **Neurodawn Pharmaceutical Co., Ltd.** · enrollment: 944 (estimated)

## Conditions studied

- Perforating Artery Infarction
- PAI

## Interventions

- **DRUG:** Y-6 tablet
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07721545
- **Lead sponsor:** Neurodawn Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-08-31
- **Primary completion:** 2028-02-28
- **Final completion:** 2028-07-31
- **Target enrollment:** 944 (ESTIMATED)
- **Last updated:** 2026-07-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07721545

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07721545, "Y-6 Sublingual Tablets for Acute Penetrating Artery Infarction". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07721545. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*